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Abstract
Background: In patients with acute respiratory distress syndrome (ARDS), it is well known that
only part of the lungs is aerated and surfactant function is impaired, but the extent of lung damage
and changes in surfactant turnover remain unclear. The objective of the study was to evaluate
surfactant disaturated-phosphatidylcholine turnover in patients with ARDS using stable isotopes.
Methods: We studied 12 patients with ARDS and 7 subjects with normal lungs. After the tracheal
instillation of a trace dose of 13C-dipalmitoyl-phosphatidylcholine, we measured the 13C enrichment
over time of palmitate residues of disaturated-phosphatidylcholine isolated from tracheal aspirates.
Data were interpreted using a model with two compartments, alveoli and lung tissue, and kinetic
parameters were derived assuming that, in controls, alveolar macrophages may degrade between
5 and 50% of disaturated-phosphatidylcholine, the rest being lost from tissue. In ARDS we assumed
that 5–100% of disaturated-phosphatidylcholine is degraded in the alveolar space, due to release of
hydrolytic enzymes. Some of the kinetic parameters were uniquely determined, while others were
identified as lower and upper bounds.
Results: In ARDS, the alveolar pool of disaturated-phosphatidylcholine was significantly lower than
in controls (0.16 ± 0.04 vs. 1.31 ± 0.40 mg/kg, p < 0.05). Fluxes between tissue and alveoli and de
novo synthesis of disaturated-phosphatidylcholine were also significantly lower, while mean resident
time in lung tissue was significantly higher in ARDS than in controls. Recycling was 16.2 ± 3.5 in
ARDS and 31.9 ± 7.3 in controls (p = 0.08).
Conclusion:  In ARDS the alveolar pool of surfactant is reduced and disaturated-
phosphatidylcholine turnover is altered.
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Background
ARDS is a syndrome of reduced gas exchange due to a dif-
fuse injury to the alveolar capillary barrier and is charac-
terized by filling of the alveoli with proteinaceous fluid,
infiltration by inflammatory cells and consolidation [1].
It may develop after a direct insult to the lung parenchyma
or it may result from inflammatory processes carried into
the lungs via the pulmonary vasculature. In the early exu-
dative phase of ARDS the massive, self-perpetuating
inflammatory process is characterized by an increased
endothelial and epithelial permeability with leakage of
plasma components.
Constriction and microembolism of the pulmonary ves-
sels are also present, leading to ventilation perfusion mis-
match. Moreover an increase in the alveolar surface
tension causes alveolar instability, atelectasis and ventila-
tory inhomogenieties. In severe ARDS, just a small frac-
tion of parenchyma remains aerated, and the damage can
be so widespread that normal parenchyma, as judged by
computed tomography, may shrink to 200–500 g [2,3].
One of the hallmarks of ARDS is reduced lung compliance
and loss of stability of terminal airways at low volumes,
suggesting surfactant dysfunction or deficiency. Samples
of bronchoalveolar lavage fluid from patients with ARDS
have low concentrations of disaturated-phosphatidylcho-
line, phosphatidylglycerol and surfactant-specific proteins
and fail to reduce surface tension both in vitro and in vivo
[4,5]. Surfactant organization in the alveoli is also altered,
since large aggregates, the active fraction of surfactant,
decrease in patients with ARDS [6]. To our knowledge, the
alveolar pool of surfactant has never been rigorously esti-
mated in patients with ARDS, nor is it known if surfactant
turnover is altered in this condition.
Data on surfactant metabolism in ARDS are available
from animal studies which showed a faster turnover rate
and a decreased alveolar pool of disaturated-phosphati-
dylcholine, while the tissue pool was increased in some
studies and unchanged in others [7-9]. However these
experiments cannot be repeated in humans and may not
necessarily mimic human disease.
In this paper we studied the turnover of surfactant disatu-
rated-phosphatidylcholine in patients with ARDS and in
control subjects. To this end we instilled a trace dose of
13C-dipalmitoyl-phosphatidylcholine into the trachea
and then followed over time the 13C enrichments in disat-
urated-phosphatidylcholine-palmitate isolated from
serial tracheal aspirates.
Available evidence indicates that surfactant dipalmitoyl-
phosphatidylcholine is recycled several times before being
degraded by alveolar macrophages or within lung paren-
chyma [7]. There is uncertainty, however, about the con-
tribution of alveolar macrophages to surfactant
catabolism, since animal experiments indicate that alveo-
lar macrophages could degrade between 5 and 50% of sur-
factant disaturated-phosphatidylcholine [10,11]. In
patients with ARDS, the fraction of disaturated-phos-
phatidylcholine degraded in the alveolar space could be
even greater than this, due to the presence of inflamma-
tory cells, bacteria and free hydrolytic enzymes [12,13].
On the basis of these considerations we assumed that
alveolar macrophages may degrade 5–50% of saturated
phosphatidylcholine in controls and 5–100% in patients
with ARDS.
Methods
Patients
We studied 12 adult patients with ARDS, defined accord-
ing to Bernard [14], and 7 subjects with normal lungs on
mechanical ventilation or breathing spontaneously
through a tracheostomy tube due to neuromuscular dis-
eases. Patients were admitted to the Intensive Care or Res-
piratory Units of the University of Padova, Italy. The study
was approved by the Ethics Committee, and written,
informed consent was obtained. After intubation with a
cuffed tube, all patients received into the trachea 20 ml of
normal saline containing 7.5 mg of 13C-dipalmitoyl-
phosphatidylcholine and 40 mg of surfactant extract
(Curosurf®, Chiesi, Parma, Italy) as spreading agent. Both
palmitates were uniformly labeled with carbon 13 ([U-
13C-PA]-DPPC, Martek-Biosciences, Columbia, MD). The
suspension was instilled close to the carina with a 4.5 mm
bronchoscope (Olympus BF-40 OD 6.0 mm Olympus-
Europe, Italy). Patients with ARDS were studied within 72
h from the onset of the acute respiratory failure and venti-
lator parameters were adjusted to maintain an oxygen sat-
uration > 85% and pH > 7.25. Ventilator and gas exchange
parameters were recorded at time 0 and subsequently
every 6 h in ARDS patients and at least once in controls.
Study design
Tracheal aspirates, collected by suction below the tip of
the endotracheal tube after instilling 5 ml of normal
saline, were obtained at baseline, every 6 h until 72 h and
then every 12 h for 7 days or until extubation. Aspirates
were filtered on gauze, centrifuged at 150-g for 10 minutes
and supernatants were stored at -20°C.
Analytical methods
Lipids from tracheal aspirates and from the administered
tracer were extracted according to Bligh and Dyer after
addition of the internal standard heptadecanoylphos-
phatidylcholine [15]. One third of the extract was oxi-
dized with osmium tetroxide. Disaturated-
phosphatidilcholine was isolated from the lipid extract by
thin layer chromatography [16], the fatty acids were deri-Respiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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vatized as pentafluorobenzyl derivatives [17], extracted
with hexane and stored at -20°C. Tracheal aspirates with
visible blood were discarded. The enrichments of 13C -
disaturated-phosphatidylcholine-palmitate were meas-
ured by gas chromatography-mass spectrometry (GC-MS,
Voyager, Thermoquest, Rodano, Milano, Italy), as previ-
ously described [18].
Data analysis
Data were analyzed with the two compartment model
shown in figure 1 under the following assumptions: a)
surfactant is distributed between two compartments
(alveoli and lung parenchyma); b) disaturated-phosphati-
dylcholine is synthesized by lung parenchyma, secreted in
the alveoli and recycled before being degraded by alveolar
macrophages or lung tissue; c) the system is at steady state
and is not perturbed by the administration of tracer. These
assumptions have been validated in adult and newborn
animals by several authors, and have been used in numer-
ous studies on surfactant turnover in experimental ani-
mals [7,19-21].
Tracer model equations are:
 (t) = -(k01 + k21)m1 (t) + k12m2 (t) + u(t)
 (t) = k21m1 (t) - (k01 + k12)m2 (t)   (1)
 m1
 m1
A two compartment model Figure 1
A two compartment model. Two compartment model for the analysis of disaturated-phosphatidylcholine-palmitate kinet-
ics. Compartment 1 is the alveolar space, compartment 2 is lung tissue. M1 and M2 are tracee disaturated-phosphatidylcholine-
palmitate masses, P is disaturated-phosphatidylcholine-palmitate de novo synthesis, F21 and F12 are inter-conversion fluxes, F01 
and F02 are irreversible loss fluxes, k21 and k12 are interconversion rate parameters, k01 and k02 are irreversible loss rate param-
eters, u is the tracer disaturated-phosphatidylcholine-palmitate input in compartment 1 and the dashed line with a bullet indi-
cates the tracer to tracee ratio (ttr) measurement. It is assumed that loss from the alveolar space is 5–50% in controls and 5–
100% in ARDS.
F21=k 21M1
alveoli
M1
P u
ttr
tissue
M2
F12=k 12M2
F02=k 02M2 F01=k 01M1Respiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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where m1 and m2 are the amount (in mg) of disaturated-
phosphatidylcholine-palmitate tracer in compartment 1
and 2 respectively,   and   (mg/h) represent their
rate of change, k21 and k12 (h-1) are inter-conversion rate
parameters, k01 and k02 (h-1) are irreversible losses, and u
is the labeled disaturated-phosphatidylcholine-palmitate
injection into the accessible compartment.
Tracee steady state equations are:
0 = -(K01 + K21)M1 + K12M2 = -F01 - F21 + F12
0 = K21M1 - (K01 + K12)M2 + P = F21 - F01 - F12 + P   (2)
where M1 and M2 (mg) are the steady state tracee disatu-
rated-phosphatidylcholine-palmitate masses in the two
compartments, P (mg/h) is disaturated-phosphatidylcho-
line-palmitate de novo synthesis, F21 = k21M1, F12 = k12M2,
F01 = k01M1, F02 = k02M2 (mg/h) are inter-conversion and
irreversible loss fluxes.
Measured tracer to tracee ratio at time t is the ratio
between tracer and tracee masses in the accessible com-
partment:
The tracer model (equations 1 and 3) is not identifiable,
since it is not possible to quantify from the input-output
tracer experiment in the alveolar compartment unique
values for the unknown parameters of the tracer model,
namely M1, k01, k02, k12, k21 [22]. Only the mass in the
alveolar compartment M1  can be uniquely identified,
together with some combinations of the original parame-
ters, namely k01+ k21, k02 + k21 and k21 k12. To resolve
model nonidentifiability, assumptions on the relative role
of the two degradation pathways need to be incorporated
into the model. Based on the results of studies in which
rabbits or mice received non-degradable analogues of
disaturated-phosphatidylcholine into the trachea [10,11],
we assumed that, in normal subjects, alveolar macro-
phages may degrade between 5 and 50% of surfactant
disaturated-phosphatidylcholine, the remaining being
degraded by lung parenchyma (i.e. F01 varies between 5
and 50% of F01+F02). In ARDS, we assumed that the deg-
radation of disaturated-phosphatidylcoline in the airways
could vary between 5 and 100% due to the degradative
activity of inflammatory cells, bacteria or enzymes
released in the alveolar spaces (i.e. F01 varies between 5
and 100% of F01+F02). Using this information, upper and
lower bounds for parameters k12, k21, k01and k02 were esti-
mated from tracer to tracee data in each individual [23].
Using these values in equation 2, upper and lower bounds
were derived for P, M2 and tracee fluxes F21 and F02, while
flux F12  was uniquely solved [22]. Additional kinetic
parameters were used to characterize the system, namely
the total mass in the system (Mtot = M1 + M2), the mean
residence time of molecules entering the system from
alveoli or lung tissue (MRT1, MRT2), defined as the sum of
the elements in column 1 and 2 of the mean residence
time matrix Θ:
and the percentage R (%) of particles that recycle back
after leaving the intracellular pool:
Upper and lower bound were calculated for Mtot, MRT1
and MRT2[22], while unique values were calculated for R.
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Table 1: Clinical characteristics of patients with ARDS and control subjects
ARDS N = 12 CONTROLS N = 7 p
Body Weight (kg) 74 ± 16 58 ± 12 0.05
Age (years) 60 ± 16 50 ± 23 0.37
Mechanical Ventilation (days) 23 ± 16 81 ± 129 0.21
Mechanical Ventilation at the start 
of the study (days)
2.6 ± 2 69 ± 132 0.23
Male/Female (number) 8/4 3/4 0.324
Survival (alive/total number) 4/12 7/7 0.006
Mean FiO2 (percentage) 60 ± 16 24 ± 14 <0.001
Mean PEEP (cm H2O) 7.7 ± 1.8 1.3 ± 0.2 <0.001
Mean AaDO2 
§ 283 ± 129 52 ± 38 <0.001
Mean PaO2/FiO2* 162 ± 50 382 ± 79 <0.001
§ AaDO2 = Mean Alveolar-arterial oxygen gradient during the study
* PaO2/FiO2 = PaO2/FiO2 ratio during the study period
Data is presented as mean ± SDRespiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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Model identifiability
Parameters k21, k12, k01, k02, and M1 of the model (figure
1) were fitted on disaturated-phosphatidylcholine-palmi-
tate tracer to tracee ratio using SAAMII [24]. Weights were
chosen optimally, i.e. equal to the inverse of the measure-
ment errors. They were assumed to be Gaussian, inde-
pendent and zero mean with a constant coefficient of
variation, which was estimated a posteriori.
Masses of palmitate residues were multiplied by 1.3025 to
obtain disaturated-posphatidycholine masses. Rate of
changes (k), fluxes (F) and synthesis (P) were multiplied
by 24 to obtain the respective values per day.
Statistical analysis
Results are presented as mean ± SEM. Data in Table 1 are
presented as mean ± SD. Differences were analysed using
the Mann-Whitney test with a 2-tailed probability of
<0.05 (SPSS 10.0, Windows 2000). Parameters, resolved
as upper and lower bounds, were considered different
when the interval of admissible values in ARDS was signif-
icantly different from the interval of admissible values in
controls.
Results
Clinical characteristics
We studied 12 ARDS patients and 7 controls. No ARDS
patient was treated with exogenous surfactant. Eight ARDS
patients (67%) died before hospital discharge, 5 for
multi-organ failure and 3 for the underlying disease.
Patients died within 4 to 18 days of study completion and
during the study respiratory and gas exchange parameters
were stable. No death occurred in the control group. In
the control group, five patients suffered from spinal mus-
cular atrophy, two had polineuropathy and one had
encephalopathy secondary to head injury. Clinical charac-
teristics of the 12 ARDS and 7 controls are reported in
Table 1. ARDS was induced by an indirect insult in all but
one patient (patient 5, Table 2). Mean age was compara-
ble in the two groups, mean weight was significantly
lower in control groups (p = 0.05) and the male/female
ratio was 8/4 in ARDS and 3/4 in controls (p = 0.26). Ven-
tilator parameters were significantly different as expected
from the study design. All ARDS patients were mechani-
cally ventilated, whereas six controls were on intermittent
ventilator support and one was breathing spontaneously
via tracheostomy tube. Table 2 reports detailed clinical
data for the 12 ARDS patients.
Kinetic calculations
The average time courses of disaturated-phosphatidylcho-
line-palmitate tracer to tracee ratio in controls and ARDS
are shown in figure 2. Although similar tracer doses were
used in ARDS and controls, the tracer to tracee ratio of
ARDS was markedly higher than in controls. In both cases,
the tracer to tracee ratio declined to negligible values at 96
h. Therefore we used data up to 96 h.
Individual curves of the tracer to tracee ratio were fitted to
the model presented in figure 1. All parameters were esti-
mated with acceptable precision, on average less than
50%. Kinetic parameters are summarized in figure 3 and
depicted in greater detail in figure 4. Three of them (M1,
F12 and R) were uniquely identified, the others are pre-
sented as ranges of values included between two extremes,
the upper and lower bounds.
In controls, the alveolar pool of disaturated-phosphati-
dylcholine was 1.31 ± 0.40 mg/kg, far smaller than the tis-
sue pool, which, depending on assumptions about
degradation of disaturated-phosphatidylcholine by alveo-
lar macrophages, ranged from 9.64 ± 2.43 to 19.35 ± 3.74
mg/kg. De novo synthesis (P) of disaturated-phosphatidyl-
choline ranged from 4.25 ± 0.7 to 8.64 ± 1.44 mg/kg/day.
Table 2: Clinical characteristics of patients with ARDS
Patient Sex Weight (kg) Age (years) Intubation‡ (days) Survival (Y/N) Main Diagnosis PaO2/FiO2M/m* (%) AaDO2M/mx§ (mmHg)
Pt1 F 48 86 24/5 N Gastric ulcer, MOSF† 221/171 140/159
Pt2 M 95 27 11/1 N Polytrauma, MOSF† 136/82 423/575
Pt3 F 57 47 6/0 N Rectal cancer, MOSF† 145/111 235/279
Pt4 M 88 69 33/3 N Sepsis post pancreatectomy 132/70 382/482
Pt5 M 90 53 49/6 Y Politrauma, lung contusions 153/63 399/608
Pt6 M 69 59 6/3 N Gastrectomy, MOSF†. 82/62. 555/590
Pt7 M 88 62 15/1 Y Sepsis 194/58 177/605
Pt8 F 52 46 47/3 Y Cyrrosis, liver transplant 146/92 276/396
Pt9 M 78 71 42/5 Y Candida Pneumonia 268/187 158/260
Pt10 M 70 61 11/4 N Gastric Cancer 156/87 214/414
Pt11 F 60 69 18/0 N Pancreatic Cancer 118/70 267/333
Pt12 M 88 74 13/5 N Pancreatitis 195/129 173/227
‡ Intubation = number of days of intubation/days of intubation at the start of the study
† MOSF = Multi Organ System Failure
* PaO2/FiO2 M/m = PaO2/FiO2 ratio Mean/minimum during the study period
§AaDO2M/mx = Alveolar-arterial oxygen gradient Mean/maximum during the study periodRespiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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Tracer to tracee ratio plot Figure 2
Tracer to tracee ratio plot. Tracer to tracee ratio (ttr) in disaturated-phosphatidylcholine and palmitate isolated from tra-
cheal aspirates in ARDS (upper) and controls (lower). Values are mean ± SEM. n = 7 for control subjects and 12 for patients 
with ARDS.
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The flux from alveoli to tissue (F21) ranged from 3.12 ±
1.49 to 4.80 ± 1.78 mg/kg/day. The flux from tissue to
alveoli (F12) was 5.23 ± 1.78 mg/kg/day and recycling (R)
was 31.9 ± 7.3%. According to the model, labelled disatu-
rated-phosphatidylcholine is expected to accumulate into
the lung parenchyma of control subjects, reaching a max-
imum concentration between 12 and 24 hours after instil-
lation. Afterwards, tissue isotopic enrichment is expected
to decrease, so that 96 hours after the start of the study
around 20% of the tracer remains associated with lung tis-
sue (data not shown).
In patients with ARDS, the alveolar pool of disaturated-
phosphatidylcholine (M1) was smaller than in controls:
0.16 ± 0.04 vs 1.31 ± 0.40 mg/kg (p < 0.05). Fluxes
between tissue and alveoli (F12 and F21) and de novo syn-
thesis (P) of disaturated-phosphatidylcholine were also
smaller than in controls. Fractional rates of transfer
between tissue and airways (k21 and k12) and alveolar
mean resident time (MRT1) were not different from con-
trols. In ARDS, the tissue mean resident time of disatu-
rated-phosphatidylcholine was significantly longer than
in controls (figure 3 and 4). Recycling tended to be
smaller in patients with ARDS, but the difference was not
significant: 16.2% ± 3.5 in ARDS and 31.9% ± 7.3 in con-
trols (p = 0.08, figure 4). Differences between ARDS and
control patients appear to be robust, since, with the excep-
tion of the synthesis rate P, all differences remained signif-
icant even assuming that in controls 5–100% of
disaturated-phosphatidycholine can be degraded in the
alveolar spaces.
The model predicts that in ARDS instilled disaturated-
phosphatidylcholine associates rapidly with lung tissue,
reaching a maximum after 12–24 hours, and then
decreases gradually, so that after 96 hours 10–30% of the
dose remains tissue-associated (not shown).
Discussion
Pulmonary surfactant is essential for normal lung func-
tion, and it is well established that surfactant impairment
contributes to respiratory failure in ARDS [4,5,25-27].
These observations prompted the use of exogenous sur-
factant in ARDS, to replenish a deficient state and reverse
surfactant inactivation [28-30]. However, large rand-
omized clinical trials have given puzzling results [28-30]
suggesting that other processes, besides surfactant dys-
function, may contribute to lung damage in ARDS or at
least indicating that exogenous surfactant is either rapidly
inactivated or is preferentially distributed to normal lung
sections.
Most of our knowledge on surfactant kinetics in acute
lung injury derives from animal studies done with radio-
Main kinetic results Figure 3
Main kinetic results. Disaturated-phosphatidylcholine-palmitate kinetics in ARDS (left) and controls (right). Unique values 
are estimated only for M1 and F12. Other parameters are presented as ranges, limited by average upper and lower bounds.
ARDS CONTROLS
0.16
mg/kg
0.14 - 0.46 mg/kg/d
0.55 mg/kg/d
0.10 - 0.41
mg/kg/d
0 - 1.85
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mg/kg/d
1.31
mg/kg
4.25 - 8.64
mg/kg/d
5.23 mg/kg/d
1.51-7.21
mg/kg
9.64-19.35
mg/kg
3.12 - 4.80 mg/kg/d
2.11 - 8.33
mg/kg/d
0.43 - 2.11
mg/kg/dRespiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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Detailed kinetic results Figure 4
Detailed kinetic results. Estimated and derived kinetic parameters of ARDS patients (black boxes) and controls (white 
boxes). Values are expressed as mean ± SEM. Symbols as in figure [1]. Stars (*) represent unique values in ARDS that were sig-
nificantly lower (p < 0.05) than the respective values in controls. Crosses (†) indicate intervals of admissible values in ARDS sig-
nificantly lower than in controls (upper bound in ARDS significantly lower than lower bound in controls). Double crosses (‡) 
indicate intervals of admissible values in ARDS significantly higher than in controls (lower bound in ARDS significantly higher 
than upper bound in controls).Respiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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active isotopes [7]. In this study we analysed the turnover
of surfactant disaturated-phosphatidylcholine in control
subjects and in patients with ARDS using stable isotopes.
The technique used has been validated in pre-term
baboons with bronchopulmonary dysplasia. In that
experiment we found that the estimate of the alveolar and
tissue pools of disaturated phosphatidylcholine obtained
from the dilution of stable isotopes in tracheal aspirates
compared well with direct measurements done at
autopsy. [31]. The technique has been also applied to
human infants with neonatal respiratory distress syn-
drome due to prematurity, lung malformations and infec-
tions [18,32-36]. However there are aspects of the present
work, both conceptual and technical, that warrant special
comment.
Basic assumptions
The design of the study assumes that the tracer was admin-
istered as a pulse, that there was good mixing between
tracer and endogenous surfactant, that the administered
material did not perturb endogenous surfactant, that tra-
cheal aspirates were representative of events happening in
the most peripheral airways and that patients were at
steady state.
While in neonatal respiratory disorders the lung paren-
chyma is relatively homogeneous, this is certainly not the
case in patients with ARDS, where areas of atelectasis and
over-distension coexist and the tracer might distribute
preferentially to aerated sections of the lungs [3]. In this
study, to optimize distribution, we mixed the tracer with
a surfactant extract used as a spreading agent. We could
not document directly in our patients that the instilled
material distributed uniformly throughout the aerated air-
ways, but we relied on the following findings all indicat-
ing that the instilled material mixed well with resident
surfactant: a) animals who receive surfactant through the
airways with the technique we used, display a rather
homogeneous distribution through the airways, [37-39];
b) our estimate of the alveolar pool of disaturated-phos-
phatidylcholine in control patients agrees very nicely with
data obtained by Rebello et al on bronchoalveolar lavage
fluid of human cadaver lungs [40]; c) in preterm baboons
we found that the disaturated-phosphatidylcholine pools
calculated from the dilution of tracers administered
through the trachea compare well with direct measure-
ments done at autopsy [31]; d) in the same experiment we
found the disaturated-phosphatidylcholine tracer enrich-
ments in tracheal aspirates were remarkably similar to the
enrichments measured in the bronchoalveolar lavage
fluid (data not shown).
The dose of disaturated-phosphatidycholine adminis-
tered to control subjects (20 ± 2 mg) represented 1.1–
2.1% of the estimated lung pool [5], an amount unlikely
to perturb endogenous surfactant. In patients with ARDS,
the dose (20 ± 2 mg) represented 5.0–13.1% of the esti-
mated lung pool, an amount also unlikely to induce a
pharmacologic effect, considering that the doses of sur-
factant used for the treatment of ARDS are at least two
orders of magnitude greater [29,30]. Since the dose of sur-
factant administered was small and clinical conditions
remained stable during the study, we assume that the sys-
tem was at steady state, thus allowing the use of a linear
time invariant compartmental model to describe disatu-
rated-phosphatidylcholine kinetics.
Data were analysed according to the two compartment
model reported in figure 1. This model is physiologically
plausible, but too complex to be uniquely resolvable from
the available data, since only the mass in the alveolar
compartment (M1), the flux from the lung tissue back to
the alveolar space (F12) and recycling (R) can be uniquely
solved. Only a far more complex experiment, with tracer
administered also in the lung tissue compartment, could
permit to uniquely identify all kinetic parameters. Since
this experiment could not be done, we used existing
knowledge on the contribution of alveolar macrophages
to surfactant degradation to derive bounds for parameters
that could not be uniquely identified. Thus, on the basis
of animal experiments done by Gurel and Rider [10,11],
we assumed that alveolar macrophages could normally
degrade between 5 and 50% of surfactant disaturated-
phosphatidylcholine, the remaining being degraded by
the lung parenchyma. It should be noted however, that
50% degradation by alveolar macrophages probably rep-
resents a maximum, since this figure was derived on the
assumption that alveolar macrophages do not re-enter
lung parenchyma after the uptake of surfactant in the alve-
oli [10]. In ARDS, we assumed that 5–100% of surfactant
disaturated-phosphatidylcoline could be degraded in the
airways, due to the degradative activity of inflammatory
cells or bacteria. By incorporating these assumptions into
the tracer-tracee model, upper and lower bounds were
derived for all non identifiable kinetic parameters, follow-
ing a strategy formalized in [23] and applied to study thy-
roid hormones [41,42] and glucose [43] kinetics.
Surfactant kinetic parameters in controls
Our estimate of the alveolar and tissue pools of disatu-
rated-phosphatidylcholine in controls agree quite well
with measurements taken by Rebello et al. during autop-
sies of adults without lung disease [40]. In fact, according
to Rebello et al. the alveolar and tissue pools contain
respectively 1.9 μmol/kg and 28.4 μmol/kg of disaturated-
phosphatidylcholine. We found that in controls the alve-
olar pool of disaturated-phosphatidylcholine was 2.3
μmol/kg, while the tissue pool ranged between 17.1 and
34.3 μmol/kg. It is also of note that our results compare
favorably with those of Martini et al. who studied sur-Respiratory Research 2007, 8:13 http://respiratory-research.com/content/8/1/13
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factant turnover in adult pigs using stable isotopes [44].
These authors reported that mean phosphatidylcholine
synthesis was 4.7 mg/kg/day, while our estimate ranged
between 4.3 and 8.6 mg/kg/day. Furthermore they
reported that the phosphatidylcholine tissue pool was 10
times higher than the alveolar pool [44], in good agree-
ment with our finding that in control subjects the tissue
pool was 7.6–14.8 times greater the alveolar pool. Over-
all, these results support our approach and also indicate
that tracheal aspirates can be as useful as bronchoalveolar
lavage fluid for the study of surfactant turnover.
Using morphometric methods Young et al. estimated that
the alveolar pool of disaturated-phosphatidylcholine is
comparable to the lamellar body pool [45]. Thus it is
likely that the tissue pool of disaturated-phosphatidylcho-
line measured with the present technique includes both
intracellular surfactant and non-surfactant membranes
that, with time, incorporate a fraction of administered
disaturated-phosphatidylcholine.
Surfactant in ARDS
In patients with ARDS alveolar pool, fluxes between tissue
and alveoli and de novo synthesis of disaturated-phos-
phatidylcholine were all smaller than in controls, while
the mean residence time in lung tissue was greater than in
controls. These differences appear to be robust, since, with
the exception of de novo synthesis, they persist even
assuming that in controls alveolar macrophages degrade
between 5% and 100% of surfactant disaturated-phos-
phatidylcholine. Thus most of our conclusions remain
valid independent of any assumption regarding the site of
degradation of surfactant.
The present results agree with the view that, in ARDS, only
a fraction of the lung is accessible to exogenous surfactant.
In fact, the decrease of the alveolar pool of disaturated-
phosphatidylcholine, the decrease of fluxes between tis-
sue and alveoli and the decrease in the rate of synthesis
can all be interpreted assuming that instilled surfactant
reached only aerated lung sections. However, our data do
not support the notion that these residual lung sections
were normal, since the mean resident time of disaturated-
phosphatidylcholine in lung parenchyma (MRT2) was
greater while the rate of recycling tended to be lower than
in controls. The greater mean residence time of disatu-
rated-phosphatidylcholine in lung tissue could be due to
a number of factors, namely to a decreased ability to
degrade surfactant components, to an increased reacyla-
tion of lysophosphatidylcholine (favored by the increased
availability of palmitate residues generated by phospholi-
pase A2, released by inflammatory cells), to a proliferation
of type II cells, to the distribution of tracer to lung struc-
tures not pertaining to the surfactant system (i.e. infiltrat-
ing inflammatory cells), or to a combination of these
phenomena [46]. The distribution of tracer to lung struc-
tures not pertaining to the surfactant system could explain
the tendency towards a less efficient recycling of DSPC
observed in patients with ARDS (figure 4).
Conclusion
Surfactant pool size is greatly diminished in ARDS com-
pared to control, and surfactant kinetics is altered in ARDS
resulting from a significantly reduced production rate and
a significantly longer retention time in the 2nd (tissue)
compartment.
The fact that the alveolar pool of disaturated-phosphati-
dylcholine can be estimated unambiguously is an impor-
tant result of this work. In future studies this approach
could be used to relate changes in surfactant turnover with
time course and severity of ARDS or to evaluate the effect
of different treatments (ventilation modes, inhaled or
intravenous therapies) on surfactant metabolism.
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